Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252011149 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Andreea-Iulia Vlădulescu-Trandafir und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, COVID-19, Immunosuppressive Agents, SARS-CoV-2. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy “Carol Davila”.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) patients face different health challenges when infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population, due to both their immunocompromised state and the immunosuppressive therapies they receive. This systematic literature review, which follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) paradigm, explores the interactions between RA and SARS-CoV-2 infection, focusing on immunologic issues, disease management, vaccination, and adverse outcomes. In order to obtain the most relevant information, we systematically reviewed the specific literature from 1 January 2021 to 31 December 2023, based on the PRISMA method, by which we eventually selected 35 eligible articles, to which we added other ISI-indexed studies to enrich our results further. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Firstly, the data collected revealed the impact of the pandemic on RA diagnoses and the fear of face-to-face medical consultations that delayed adequate treatment. Secondly, cardiovascular and metabolic comorbidities increase the risk of prolonged COVID-19 symptoms, hospitalization, and severe COVID-19 outcomes for RA patients. With respect to immunosuppressive treatment used to control RA, it was observed that glucocorticoids (especially high-dose usage) and Rituximab (RTX) predispose the patients to poor SARS-CoV-2 outcomes, as opposed to Baricitinib and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) inhibitors. COVID-19 vaccination has proven effective and generally safe for RA patients in some studies, although therapies with Methotrexate (MTX), Abatacept (ABA), and RTX have been associated with impaired vaccine immune response. This systematic literature review brings updated and thorough information with respect to the immunological, clinical, and management of a complex immune-mediated inflammatory disease (IMID) like RA in the setting of COVID-19 and underlines the challenges faced by this group of patients. The lessons learned can be extended beyond the pandemic in shaping a more informed and compassionate healthcare system and offering long-term medical care for patients with RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
- Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital "Bagdasar-Arseni", 041915 Bucharest, Romania.
- Internal Medicine and Rheumatology Departments, "Sfânta Maria" Hospital, 011172 Bucharest, Romania.
- Faculty of Medical Bioengineering, University of Medicine and Pharmacy "Grigore T. Popa" Iasi, 700454 Iasi, Romania.
- Faculty of Midwifery and Nursing, University of Medicine and Pharmacy "Carol Davila", 020022 Bucharest, Romania.
- Gerontology and Geriatrics Clinic Division, St. Luca Hospital for Chronic Illnesses, 041915 Bucharest, Romania.
ORCID-Profile: Andreea-Iulia Vlădulescu-Trandafir, Constantin Munteanu, Aurelian Anghelescu, Sorina Aurelian, Gelu Onose
Förderung
- University of Medicine and Pharmacy “Carol Davila”
Zitieren
APA
Vlădulescu-Trandafir, A. I., Bojincă, V. C., Munteanu, C., Anghelescu, A., Popescu, C., Stoica, S. I., Aurelian, S., Bălănescu, A., Băetu, C., Ciobanu, V., & Onose, G. (2024). Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011149
Vancouver
Vlădulescu-Trandafir AI, Bojincă VC, Munteanu C, Anghelescu A, Popescu C, Stoica SI, et al. Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011149
BibTeX
@article{VldulescuTrandafir2024,
author = {Vlădulescu-Trandafir, Andreea-Iulia and Bojincă, Violeta-Claudia and Munteanu, Constantin and Anghelescu, Aurelian and Popescu, Cristina and Stoica, Simona-Isabelle and Aurelian, Sorina and Bălănescu, Andra and Băetu, Cristina and Ciobanu, Vlad and Onose, Gelu},
title = {Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252011149}
}
EUVIMED